Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases

Lixisenatide reduces amyloid plaques, neurofibrillary tangles and neuroinflammation in an APP/PS1/tau mouse model of Alzheimer's disease

(2018) Hong-Yan Cai et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease

(2018) Jingjing Tai et al.   BRAIN RESEARCH

DA5-CH, a novel GLP-1/GIP dual agonist, effectively ameliorates the cognitive impairments and pathology in the APP/PS1 mouse model of Alzheimer's disease

(2018) Yue Cao et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Alzheimer’s Disease, Oligomers, and Inflammation

(2018) Gianluigi Forloni et al.   JOURNAL OF ALZHEIMERS DISEASE

The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease

(2018) Andre F Batista et al.   JOURNAL OF PATHOLOGY

Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease

(2018) Seung Pil Yun et al.   NATURE MEDICINE

Glucagon-like peptide 1 in health and disease

(2018) Andreas Andersen et al.   Nature Reviews Endocrinology

Brain insulin resistance in type 2 diabetes and Alzheimer disease: concepts and conundrums

(2018) Steven E. Arnold et al.   Nature Reviews Neurology

Diabetes mellitus and Parkinson disease

(2018) Gennaro Pagano et al.   NEUROLOGY

Association between diabetes and subsequent Parkinson disease

(2018) Eduardo De Pablo-Fernandez et al.   NEUROLOGY

Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse model

(2018) Liping Zhang et al.   NEUROPEPTIDES

Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease

(2018) Peng Feng et al.   NEUROPHARMACOLOGY

Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models

(2018) Christian Hölscher   NEUROPHARMACOLOGY

Characterization and clinical use of inflammatory cerebrospinal fluid protein markers in Alzheimer’s disease

(2018) Frederic Brosseron et al.   Alzheimers Research & Therapy

Subcutaneous Administration of Liraglutide Ameliorates Alzheimer-Associated Tau Hyperphosphorylation in Rats with Type 2 Diabetes1

(2018) Yan Yang et al.   JOURNAL OF ALZHEIMERS DISEASE

Diabetes and Hypercholesterolemia Increase Blood-Brain Barrier Permeability and Brain Amyloid Deposition: Beneficial Effects of the LpPLA2 Inhibitor Darapladib

(2018) Nimish K. Acharya et al.   JOURNAL OF ALZHEIMERS DISEASE

D-Ala2GIP Facilitated Synaptic Plasticity and Reduces Plaque Load in Aged Wild Type Mice and in an Alzheimer's Disease Mouse Model

(2018) Emilie Faivre et al.   JOURNAL OF ALZHEIMERS DISEASE

A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects

(2017) Jie Zhou et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease

(2017) Ziyue Yuan et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation

(2017) Yanwei Li et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Reactive Astrocytes: Production, Function, and Therapeutic Potential

(2017) Shane A. Liddelow et al.   IMMUNITY

Liraglutide promotes improvements in objective measures of cognitive dysfunction in individuals with mood disorders: A pilot, open-label study

(2017) Rodrigo B. Mansur et al.   JOURNAL OF AFFECTIVE DISORDERS

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

(2017) Dilan Athauda et al.   LANCET

Increased risk of Parkinson disease with diabetes mellitus in a population-based study

(2017) Yu-Wan Yang et al.   MEDICINE

Mild cognitive impairment as a risk factor for Parkinson's disease dementia

(2017) Jeroen Hoogland et al.   MOVEMENT DISORDERS

Inflammation, metaflammation and immunometabolic disorders

(2017) Gökhan S. Hotamisligil   NATURE

Neurotoxic reactive astrocytes are induced by activated microglia

(2017) Shane A. Liddelow et al.   NATURE

Biochemical and cellular properties of insulin receptor signalling

(2017) Rebecca A. Haeusler et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Liraglutide Improves Water Maze Learning and Memory Performance While Reduces Hyperphosphorylation of Tau and Neurofilaments in APP/PS1/Tau Triple Transgenic Mice

(2017) Shuyi Chen et al.   NEUROCHEMICAL RESEARCH

A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease

(2017) Jaishree Jalewa et al.   NEUROPHARMACOLOGY

Role of neuroinflammation in neurodegeneration: new insights

(2017) Róisín M. McManus et al.   Alzheimers Research & Therapy

Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice

(2017) Sigrid Jall et al.   Molecular Metabolism

GLP-1 Receptor Stimulation Reduces Amyloid-β Peptide Accumulation and Cytotoxicity in Cellular and Animal Models of Alzheimer's Disease

(2017) Yazhou Li et al.   JOURNAL OF ALZHEIMERS DISEASE

Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’

(2016) M. A. Skow et al.   DIABETES OBESITY & METABOLISM

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors

(2016) M. Nauck   DIABETES OBESITY & METABOLISM

GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial

(2016) Olivia M. Farr et al.   DIABETOLOGIA

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

Subcutaneous administration of liraglutide ameliorates learning and memory impairment by modulating tau hyperphosphorylation via the glycogen synthase kinase-3β pathway in an amyloid β protein induced alzheimer disease mouse model

(2016) Liqin Qi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cross Talk Between Brain Innate Immunity and Serotonin Signaling Underlies Depressive-Like Behavior Induced by Alzheimer's Amyloid-  Oligomers in Mice

(2016) J. H. Ledo et al.   JOURNAL OF NEUROSCIENCE

Liraglutide prevents beta-amyloid-induced neurotoxicity in SH-SY5Y cells via a PI3K-dependent signaling pathway

(2016) Xiao-Ying Liu et al.   NEUROLOGICAL RESEARCH

Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model

(2016) Yanwei Li et al.   NEUROPHARMACOLOGY

Challenges in detecting disease modification in Parkinson's disease clinical trials

(2016) Dilan Athauda et al.   PARKINSONISM & RELATED DISORDERS

Long-Term Treatment with Liraglutide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, Has No Effect on β-Amyloid Plaque Load in Two Transgenic APP/PS1 Mouse Models of Alzheimer’s Disease

(2016) Henrik H. Hansen et al.   PLoS One

In Alzheimer’s Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial

(2016) Michael Gejl et al.   Frontiers in Aging Neuroscience

Possible Integrative Actions of Leptin and Insulin Signaling in the Hypothalamus Targeting Energy Homeostasis

(2016) Mina Thon et al.   Frontiers in Endocrinology

Prophylactic liraglutide treatment prevents amyloid plaque deposition, chronic inflammation and memory impairment in APP/PS1 mice

(2015) Paula L. McClean et al.   BEHAVIOURAL BRAIN RESEARCH

Plasma Insulin-Like Growth Factor 1 Is Associated with Cognitive Impairment in Parkinson's Disease

(2015) Jianfang Ma et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Hippocampal Insulin Resistance Impairs Spatial Learning and Synaptic Plasticity

(2015) Claudia A. Grillo et al.   DIABETES

Expression and Distribution of Glucagon-Like Peptide-1 Receptor mRNA, Protein and Binding in the Male Nonhuman Primate (Macaca mulatta) Brain

(2015) Kristy M. Heppner et al.   ENDOCRINOLOGY

Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes

(2015) M Christensen et al.   INTERNATIONAL JOURNAL OF OBESITY

Parkinson's disease

(2015) Lorraine V Kalia et al.   LANCET

Neuroinflammation in Alzheimer's disease

(2015) Michael T Heneka et al.   LANCET NEUROLOGY

Hippocampal insulin resistance and cognitive dysfunction

(2015) Geert Jan Biessels et al.   NATURE REVIEWS NEUROSCIENCE

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease

(2015) W. Liu et al.   NEUROSCIENCE

Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease

(2015) Darleen A. Sandoval et al.   PHYSIOLOGICAL REVIEWS

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

(2015) Iciar Aviles-Olmos et al.   Journal of Parkinsons Disease

Distribution and characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain

(2015) Simon C. Cork et al.   Molecular Metabolism

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

(2015) Annachiara Uccellatore et al.   Diabetes Therapy

Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists

(2015) Annachiara Uccellatore et al.   Diabetes Therapy

Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer's disease

(2014) Sergio T. Ferreira et al.   Alzheimers & Dementia

How does brain insulin resistance develop in Alzheimer's disease?

(2014) Fernanda G. De Felice et al.   Alzheimers & Dementia

Inflammation, Defective Insulin Signaling, and Mitochondrial Dysfunction as Common Molecular Denominators Connecting Type 2 Diabetes to Alzheimer Disease

(2014) F. G. De Felice et al.   DIABETES

Insulin Regulates Brain Function, but How Does It Get There?

(2014) S. M. Gray et al.   DIABETES

Body Fluid Cytokine Levels in Mild Cognitive Impairment and Alzheimer’s Disease: a Comparative Overview

(2014) Frederic Brosseron et al.   MOLECULAR NEUROBIOLOGY

The spectrum of cognitive impairment in Lewy body diseases

(2014) Jennifer G. Goldman et al.   MOVEMENT DISORDERS

Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease

(2014) Paula L. McClean et al.   NEUROPHARMACOLOGY

BioEssays 11∕2013

(2013)   BIOESSAYS

TNF-α Mediates PKR-Dependent Memory Impairment and Brain IRS-1 Inhibition Induced by Alzheimer’s β-Amyloid Oligomers in Mice and Monkeys

(2013) Mychael V. Lourenco et al.   Cell Metabolism

Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action

(2013) Jonathan E. Campbell et al.   Cell Metabolism

Exenatide and the treatment of patients with Parkinson’s disease

(2013) Iciar Aviles-Olmos et al.   JOURNAL OF CLINICAL INVESTIGATION

Neuroprotective and anti-apoptotic effects of liraglutide on SH-SY5Y cells exposed to methylglyoxal stress

(2013) Mohit K. Sharma et al.   JOURNAL OF NEUROCHEMISTRY

Parkinson’s disease: an update on pathogenesis and treatment

(2013) Tom Foltynie et al.   JOURNAL OF NEUROLOGY

Tau Accumulation Activates the Unfolded Protein Response by Impairing Endoplasmic Reticulum-Associated Degradation

(2013) J. F. Abisambra et al.   JOURNAL OF NEUROSCIENCE

Cognitive Change in Newly-Diagnosed Patients with Parkinson's Disease: A 5-Year Follow-up Study

(2013) Mark Broeders et al.   JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY

How insulin engages its primary binding site on the insulin receptor

(2013) John G. Menting et al.   NATURE

Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease

(2013) Laura Dunn et al.   NEUROBIOLOGY OF AGING

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease

(2013) Paula L. McClean et al.   NEUROPHARMACOLOGY

Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans

(2013) B. Finan et al.   Science Translational Medicine

Effect of insulin on excitatory synaptic transmission onto dopamine neurons of the ventral tegmental area in a mouse model of hyperinsulinemia

(2013) S Liu et al.   Nutrition & Diabetes

Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis

(2012) Kerry Hunter et al.   BMC NEUROSCIENCE

Parkinson's disease, insulin resistance and novel agents of neuroprotection

(2012) Iciar Aviles-Olmos et al.   BRAIN

An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomers

(2012) Theresa R. Bomfim et al.   JOURNAL OF CLINICAL INVESTIGATION

Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline

(2012) Konrad Talbot et al.   JOURNAL OF CLINICAL INVESTIGATION

Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin

(2012) M K Piya et al.   JOURNAL OF ENDOCRINOLOGY

Insulin in the Brain: Sources, Localization and Functions

(2012) Rasoul Ghasemi et al.   MOLECULAR NEUROBIOLOGY

Amyloid-β oligomers link depressive-like behavior and cognitive deficits in mice

(2012) J H Ledo et al.   MOLECULAR PSYCHIATRY

Risk of Alzheimer’s Disease in Relation to Diabetes: A Population-Based Cohort Study

(2012) Kai-Chen Wang et al.   NEUROEPIDEMIOLOGY

Preproglucagon (PPG) neurons innervate neurochemicallyidentified autonomic neurons in the mouse brainstem

(2012) I.J. Llewellyn-Smith et al.   NEUROSCIENCE

The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease

(2012) A.M. Duffy et al.   NEUROSCIENCE

Insulin in the brain: There and back again

(2012) William A. Banks et al.   PHARMACOLOGY & THERAPEUTICS

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Inflammatory Mechanisms in Obesity

(2011) Margaret F. Gregor et al.   Annual Review of Immunology

Serum Insulinlike Growth Factor 1 as Possible Marker for Risk and Early Diagnosis of Parkinson Disease

(2011) Jana Godau   ARCHIVES OF NEUROLOGY

Diabetes and Risk of Parkinson's Disease

(2011) Q. Xu et al.   DIABETES CARE

Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice

(2011) Emilie Faivre et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Insulin resistance impairs nigrostriatal dopamine function

(2011) J.K. Morris et al.   EXPERIMENTAL NEUROLOGY

The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease

(2011) P. L. McClean et al.   JOURNAL OF NEUROSCIENCE

Resolving controversies on the path to Alzheimer's therapeutics

(2011) Dennis J Selkoe   NATURE MEDICINE

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease

(2011) Sergio T. Ferreira et al.   NEUROBIOLOGY OF LEARNING AND MEMORY

Preproglucagon neurons project widely to autonomic control areas in the mouse brain

(2011) I.J. Llewellyn-Smith et al.   NEUROSCIENCE

Endoplasmic reticulum stress, obesity and diabetes

(2011) Miriam Cnop et al.   TRENDS IN MOLECULAR MEDICINE

Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet

(2010) Jill K. Morris et al.   AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY

A Meta-Analysis of Cytokines in Alzheimer's Disease

(2010) Walter Swardfager et al.   BIOLOGICAL PSYCHIATRY

Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson’s disease

(2010) Farhad Mashayekhi et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Insulin resistance is associated with the pathology of Alzheimer disease: The Hisayama Study

(2010) T. Matsuzaki et al.   NEUROLOGY

Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes

(2010) Ulrich Werner et al.   REGULATORY PEPTIDES

The Unfolded Protein Response Is Activated in Pretangle Neurons in Alzheimer's Disease Hippocampus

(2009) Jeroen J.M. Hoozemans et al.   AMERICAN JOURNAL OF PATHOLOGY

The Role of Metabolic Disorders in Alzheimer Disease and Vascular Dementia

(2009) Suzanne Craft   ARCHIVES OF NEUROLOGY

Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease

(2009) Talib Abbas et al.   BEHAVIOURAL BRAIN RESEARCH

Endoplasmic Reticulum Protein Quality Control in Neurodegenerative Disease: The Good, the Bad and the Therapy

(2009) Wiep Scheper et al.   CURRENT MEDICINAL CHEMISTRY

Is There an Association between the Level of High-Sensitivity C-Reactive Protein and Idiopathic Parkinson’s Disease? A Comparison of Parkinson’s Disease Patients, Disease Controls and Healthy Individuals

(2009) In-Uk Song et al.   EUROPEAN NEUROLOGY

The major inflammatory mediator interleukin-6 and obesity

(2009) Katalin Eder et al.   INFLAMMATION RESEARCH

Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease

(2009) Sehee Kim et al.   JOURNAL OF ENDOCRINOLOGY

 -Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin

(2009) Q.-L. Ma et al.   JOURNAL OF NEUROSCIENCE

Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases

(2009) M. Reale et al.   MINI-REVIEWS IN MEDICINAL CHEMISTRY

Cortical hypometabolism assessed by a metabolic ratio in Parkinson's disease primarily reflects cognitive deterioration-[18F]FDG-PET

(2009) Inga Liepelt et al.   MOVEMENT DISORDERS

Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers

(2009) Fernanda G. De Felice et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

(2009) Y. Li et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Diabetes in Patients With Idiopathic Parkinson's Disease

(2008) C. Becker et al.   DIABETES CARE

Glucagon-like peptide 1 receptor stimulation by exendin-4 reverses key deficits in distinct rodent models of Parkinson's disease

(2008) Alexander Harkavyi et al.   Journal of Neuroinflammation

Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling

(2008) Aileen M. Moloney et al.   NEUROBIOLOGY OF AGING

Insulin Receptor Signaling Regulates Synapse Number, Dendritic Plasticity, and Circuit Function In Vivo

(2008) Shu-Ling Chiu et al.   NEURON

Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism

(2008) Bogdan Brodacki et al.   NEUROSCIENCE LETTERS

Amyloid beta oligomers induce impairment of neuronal insulin receptors

(2007) Wei-Qin Zhao et al.   FASEB JOURNAL

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease

(2007) Göran Bertilsson et al.   JOURNAL OF NEUROSCIENCE RESEARCH